1.,6$h5h1%√∏/*√∏6√∏ 
1. BE √π(5√∏ 7,%%√∏ √úR√úN√úN ADI 
LAFLEKS LAKTATLI 5√∏1*(5dg=(/7√∏6√∏ 
2. KAL √∏TAT √∏F VE KANT √∏TAT √∏F B √∏LE √π√∏ M
Etkin maddeler: 
Her bir litre √ß√∂zelti Sodyum laktat: 3,1 gram (3,1 mg/ml) 
Sodyum klor√ºr: 6 gram (6 mg/ml) 
Potasyum klor√ºr: 0.3 gram (0.3 mg/ml) 
Kalsiyum klor√ºr dihidrat: 0.2 gram (0.2 mg/ml) 
√á√∂zeltideki HOHNWUROLWNRQVDQWUDV\RQODU√ïP(TOPPROO
- Sodyum: 130 (130) 
- Kalsiyum: 3 (1.5) 
- Klor√ºr: 109 (109) 
- Potasyum: 4 (4) 
- Laktat: 28 (28) 
<DUG√ïPF√ïPDGGHOHU 
<DUG√ïPF√ïPDGGHOHULoLQ¬∂HEDN√ïQ√ï]
3. FARMAS√ñT √∏K FORM 
√∏QWUDYHQ|]LQI¬Å]\RQYHVWHULOLULJDV\RQLoLQ berrak, renksiz, steril √ß√∂zelti.
4. KL √∏N√∏K √ñZELL √∏KLER 
4.1 Terap√∂tik endikasyonlar 
-6√ïY√ïND\√ïSODU√ïQGDYHKLSRQDWUHPLGXUXPXQGDNLSDUHQWHUDOV√ïY√ïWHGDYLVLQGH (Organizmadaki b√ºy√ºk 
V√ïY√ï ND\√ïSODU√ïQGD HNVWUDVHO¬ÅOHU V√ïY√ïODU√ïQ ELOH√∫LPLQGH GH√∑L√∫LNOL N \DSPDGDQ KDVWDGDNL V√ïY√ï YH
HOHNWUROLWGHQJHVLQLVD√∑ODU
x√∏]RWRQLNVRG\XPYHV√ïY√ïUHSODVPDQ√ïDPDF√ï\OD2x(NVWUDVHO¬ÅOHUV√ïY√ïKDFPLQLQG¬Å]HOWLOHUHNRUJDQL]PDGDNLV√ïY√ïYHHO HNWUROLWJHUHNVLQLPLQLQ
NDU√∫√ïODQPDV√ïQGD
- Organizmadaki asit- ED]GHQJHVLQLQDVLWWDUDIDND\G√ï√∑√ïGXUXPODUGDPHWDEROLNDVLGR]GDKHP 
DVLGR]KDOLQLRUWDGDQNDOG√ïU√ïUKHPGHE|\OHYDNDODUGDPHYFXWRODQHNV WUDVHO¬ÅOHUV√ïY√ïND\E√ïQ√ï
NDU√∫√ïODU
xMetabolik asidoz. 
xDiyabet ketozu.  
x√áocuk diyareleri.  
x$√∑√ïUHQIHNVL\RQKDVWDO√ïNODU√ï
x+DILIE|EUHN\HWPH]OL√∑L
x.D√∫HNVL
x.HWRMHQLNGL\HWOHUYHDVLWOH√∫WLULFLLODoODU
-√∏ULJDV\RQDPDoO√ïNXOODQ√ïP√ï
xYara ve kesilerin irigasyonunda 
x'LDJQRVWLNDPDoO√ïDUWURVNRSLNLQFHOHPHOHUGH
x7HGDYLDPDoO√ïGHYDPO√ï\DGDDUDO√ïNO√ïLULJDV\RQODUGD
x$o√ïNNDOSFHUUDKLVLQGH¬≥3ULPLQJ √á√∂zelti‚Äù olarak 
x7UDQVSODQWDV\RQODUGD \D GD Do√ïN NDOS DPHOL\DWODU√ïQGD SHU operatuvar b√∂lgesel hipotermi 
VD√∑ODPDNLoLQVOXVK √ß√∂zelti olarak. 
4.2 Pozoloji ve uygulama √∫ekli 
Pozoloji / Uygulama V√ïNO√ï√∑√ï ve s√ºresi: 
√∏QWUDYHQ|]LQI¬Å]\RQODX\JXODPDGD 
Uygulanacak doz ve LQI¬Å]\RQK√ï]√ïKDVWDQ√ïQ\D√∫√ïQDD√∑√ïUO√ï√∑√ïQD klinik ve biyolojik durumuna  (asit-
ED]GHQJHVLQHYHELUOLNWHX\JXODQDQWHGDYL\HJ|UHKHNLPWDUDI√ïQGDQD\DUODQ√ïU
*HQHORODUDNGRNWRUWDUDI√ïQGDQED√∫NDW¬ÅUO¬Å|QHULOPHGL\VHHUL√∫NLQDG|OHVDQYH\D√∫O √ïODUGDVDDWWH
1 ‚Äì 3 litre √∂nerilir. 38\JXODPDV√ïNO√ï√∑√ïKDVWDQ√ïQNOLQLNGXUXPXQDJ|UHKHNLPWDUDI√ïQGDQD\DUODQ√ïU(UL√∫ NLQYH\D√∫O√ïODUGD
JHQHOGHVDDWWHNLORED√∫√ïQD -POYHULOHELOLU.DOSKDVWDO√ï√∑√ï v.b.GXUXPODU\RNVDYHULOPHK√ï]√ïVDDWWH
NLORED√∫√ïQDPO
\HNDGDUDUWW√ïU√ïODELOLU
Ameliyatlarda ve gereksinim GXUXPXQGDLQI¬Å]\RQK√ï]√ïYHX\JXODQDQWRSODPKDFLPDUWW√ïU√ïODELOLU
.DQND\√ïSODU√ïQGDJHQHORODUDNQRUPDONDQKDFPLQLVD√∑ODPDNLoLQND\EHGLOHQNDQP LNWDU√ïQ√ïQ -5
NDW√ï/$)/(.6/$.7$7/,5√∏1*(5dg=(/7√∏6√∏ gerekir. 
Uygulama √∫ekli: 
Uygulama steril setlerle intra YHQ|]\ROGDQ\DS√ïO√ïU√∏QWUDYHQ|]X\JXODPD\ODLOJLOLD\U√ïQW√ïODUL oLQ
E|O¬ÅP¬∂\DEDN√ïQ√ï]
√∏ULJDV\RQDPDoO√ïX\JXODPDGD 
Doz: 8\JXODPDQ√ïQ\DGDRSHUDV\RQXQJHUHNWLUGL√∑LPLNWDUODUGDYHKHNLPLQ aU]XHWWL√∑L dozlarda 
NXOODQ√ïO√ïU
8\JXODPD√∫HNOL 
xKesi YH \DUDODU√ïQ LULJDV\RQXQGD .XOODQ√ïODFD√∑√ï E|OJH\H GR√∑UXGDQ G|NPH √∫HNO LQGH
NXOODQ√ïO√ïU
xArtroskopik inceleme YH JLUL√∫LPOHUGH 8\JXODPD VWHULO setlerle intraartik√ºler yoldan 
\DS√ïO√ïU
xPriming √ß√∂zelti RODUDNNXOODQ√ïPGD.DOS -DNFL√∑HUPDNLQDV√ïQDGR√∑UXGDQG|NP e√∫HNOLQGH
NXOODQ√ïO√ïU
xSlush √ß√∂zelti RODUDNNXOODQ√ïPGD Torba LoLQGH\DU√ïGRQPX√∫KDOHVOXVKJHWLULOHUHNE|OJHVHO
hipotermi VD√∑ODQPDV√ïLVWHQL len b√∂lgeye GR√∑UXGDQG|NPH√∫HNOLQGHNXOODQ√ïO√ïU
√ñzel pop√ºlasyonlara ili √∫kin ek bilgiler: 
%|EUHN.DUDFL√∑HU\HWPH]OL√∑L 
%XSRS¬ÅODV\RQD|]HOJHUoHNOH√∫WLULOHQELUoDO√ï√∫PDEXOXQPDG√ï√∑√ïQGDQEXKDVWD JUXEXLoLQ|]HOELU
GR]DM|QHULVLEXOXQPDPDNWDG√ïU
.DUDFL√∑HU \HWPH]OL√∑L RODQ KDVWDODUGD ODNWDW PHWDEROL]PDV √ï ER]XODELOHFH√∑LQGHQ LAFLEKS 
/$.7$7/,5√∏1*(5dg=(/7√∏6√∏ alkalile √∫WLULFLHWNLVLQLJ|VWHUHPH\HELOLU4Pediyatrik pop√ºlasyon: 
8\JXODQDFDNGR]YHLQI¬Å]\RQK√ï]√ïHUL√∫NLQOHUGHNLJLELKDVWDQ√ïQD√∑√ïUO√ï √∑√ïQDNOLQLNYHEL\RORMLN
GXUXPXQDYHELUOLNWHX\JXODQDQWHGDYL\HJ|UHKHNLPWDUDI√ïQGDQD\DUODQ√ïU
Bu pop√ºlasyonda genel olarak 24 saatte 20- PONJGR]XQGD|QHULOLUYHEXGR]Y¬ÅFXWD√∑√ïUO√ï√∑√ïQD
J|UHD√∫D√∑√ïGDNL√∫HNLOGHD\DUODQ√ïU
10 kg‚Äôdan hafif bebekler: 100 ml/kg/g√ºn 
LOHNJDUDV√ïEHEHNYHoRFXNODUPONJ¬Å]HULKHUNLORLoLQPONJJ √ºn 
NJ¬∂GDQD√∑√ïUoRFXNODUPONJ¬Å]HULKHUNLORLoLQPONJJ¬ÅQ
<DQ√ïNO√ïoRFXNODUGDLONVDDWWHRUWDODPDPONJ\DQ√ïNRUDQ√ïGR]XQGD YHLNLQFLJ¬ÅQ
PONJ\DQ√ïNRUDQ√ïGR]XQGDX\JXODQPDV√ï|QHULOLU
√πLGGHWOLNDIDWUDYPDV√ïJHoLUPL√∫oRFXN larda ortalama doz 2.850 ml/m 2'dir. 
Geriyatrik pop√ºlasyon: 
8\JXODQDFDNGR]YHLQI¬Å]\RQK√ï]√ïHUL√∫NLQOHUGHNLJLELKDVWDQ√ïQD√∑√ïUO√ï √∑√ïQDNOLQLNYHEL\RORMLN
GXUXPXQDYHELUOLNWHX\JXODQDQWHGDYL\HJ|UHKHNLPWDUDI√ïQGDQD\DUODQ√ïU
4.3. Kontrendikasyonlar 
xKar DFL√∑HUKDVWDO√ïNODU√ïYHDQRNVLNGXUXPODUJLELODNWDWPHWDEROL]PDV √ïQ√ïQD√∑√ïUGHUHFHGH
ER]XOGX√∑XKDOOHU
x$GGLVRQKDVWDO√ï√∑√ï+LoWHGDYLHGLOPHPL√∫YDNDODUGD\DGDNUL]HV QDV√ïQGDSRWDV\XPVX]
√ß√∂zeltiler tercih edilmelidir). 
x$√∑√ïUPHWDEROLNDVLGR]
xMetabolik veya respiratuvar alkaloz. 
xLaktik asidoz. 
xEkstrasel√ºler hiperhidrasyon veya hipervolemi. 
x$√∑√ïUE|EUHN\HWPH]OL√∑LROLJ¬ÅULDQ¬ÅULLOHELUOLNWHRODQ
x'HNRPSDQVHNDOS\HWPH]OL√∑L
xHiperkalemi. 
xHipernatremi. 5xHiperkalsemi. 
xHiperkloremi. 
xGenel √∂dem ve asitli siroz. 
x'LMLWDOWHGDYLVLLOHELUOLNWHNXOODQ√ïP%N]'L√∑HUW√ïEEL¬ÅU¬ÅQOHU LOHHWNLOH√∫LPOHUYHGL√∑HU
HWNLOH√∫LP√∫HNLOOHUL
x28 g√ºnl√ºkten k√º√ß√ºk yeni GR√∑DQ EHEHNOHUGH GL√∑HU NDOVL\XP LoHUHQ √ß√∂zeltiler gibi 
/$)/(.6/$.7$7/,5√∏1*(5dg=(/7√∏6√∏¬∂QLQH VHIWULDNVRQLOH ELUOLNWHNXOODQ√ïP√ï -
D\U√ïLQI¬Å]\RQKDWODU√ïQGDQX\JXODQVDODUELOH -NRQWUHQGLNHGLU\HQLGR√∑DQ√ïQNDQDN√ïP√ïQGD
fatal seftriakson-kalsiyum tuzu presipitasyonu nedeniyle) 
x(UL√∫NLQOHU GDKLO  J¬ÅQO¬ÅNWHQ E¬Å\¬ÅN KDVWDODUGD VHIWULDNVR n, LAFLEKS LAKTATLI 
5√∏1*(5dg=(/7√∏6√∏ dahil kalsiyum i√ßeren √ß√∂zeltilerle D\Q√ïLQI¬Å]\RQKDWW√ïQGDQ|UQ< -
tipi ELU NRQHNW|UGHQ H√∫ ]DPDQO√ï NXOODQ√ïOPDPDO√ïG√ïU $UG√ï√∫√ïN X\JXODPDODU L oLQ D\Q√ï
X\JXODPD VHWL NXOODQ√ïODFDNVD X\JXODPD |QFHVLQGH VHW JHoLPOL √ß√∂zeltilerle iyice 
\√ïNDQPDO√ïG√ïU
x/$)/(.6/$.7$7/,5√∏1*(562/h6<218 ,VRG\XPODNWDWDD√∫√ïU√ïGX\DUO√ïO√ï√∑√ïROGX√∑X
bilinen hastalarda kontrendikedir. 
x(OHNWURNRWHU NXOODQ√ïP√ïQ√ïQ JHUHNOL ROGX√∑X RSHUDV\RQODUGD HOHNWUROLW LoHU HQ LULJDV\RQ 
√ß√∂zeltileri NXOODQ√ïOPDPDO√ïG√ïU
4. g]HONXOODQ√ïPX\DU√ïODU√ïYH|QOHPOHUL 
√∏QWUDYHQ|] √ß√∂zeltilerin X\JXODQPDV√ï VHUXP HOHNWUROLW NRQVDQWUDV\RQXQGD GLO¬ÅV\RQ D√∫√ïU√ï
KLGUDV\RQNRQMHVWLIGXUXPODUYH\DSXOPRQHU|GHPROX√∫WXUDFDN√∫HNLOGHV√ïY√ï YHYH\D sol√ºt 
y√ºklenmesine yol a√ßabilir. Dil√ºsyon risk LHOHNWUROLWNRQVDQWUDV\RQX\ODWHUVRUDQW√ïO√ïG√ïU3HULIHULNYH
SXOPRQHU |GHPH \RO DoDELOHQ NRQMHVWLI GXUXPODU√ïQ JHOL√∫PH ULVNL LVH √ß√∂zeltideki elektrolit 
NRQVDQWUDV\RQX\ODGR√∑UXRUDQW√ïO√ïG√ïU
Kardiyak ya da pulmoner yetmezlikli hastalarda y√ºksek hacimli inf √ºzyonlar √∂zel dikkatle 
X\JXODQPDO√ïG√ïU
Sodyum klor√ºr i√ßeren √ß√∂zeltiler hipertansiyon, kalp y HWPH]OL√∑LSHULIHULN\DGDSXOPRQHU|GHP
YH\D E|EUHN IRQNVL\RQODU√ïQ√ïQ ER]XN ROGX√∑X GXUXPODUGD SUHHNODPSVL DOGRVWHURQL]P \D GD
VRG\XPELULNLPL\OHVH\UHGHQGL√∑HUGX rum ve tedavilerde dikkatle NXOODQ√ïOPDO√ïG√ïU$\Q√ï zamanda 
Bkz. B√∂l√ºm 4.5). 63RWDV\XPWX]ODU√ïLoHUHQ √ß√∂zeltiler NDOSKDVWDODU√ïQGDYHUHQDO veya adrenokortikal yetmezlik, akut 
GHKLGUDWDV\RQYHFLGGL\DQ√ïNGXUXPODU√ïQGDNLD√∫√ïU√ïGRNX\√ïN√ïP√ïJLELKLSHUNDOH PL\H \DWN√ïQO√ïN
\DUDWDQGXUXPODUGDGLNNDWOLNXOODQ√ïOPDO√ïG√ïU
/$)/(.6/$.7$7/,5√∏1*(5dg=(/7√∏6√∏ELOH√∫LPLQGHNL SRWDV\XPP LNWDU√ïSOD]PDQ√ïQNLQH 
benzer ROPDV√ïQD UD√∑PHQ√∫LGGHWOLSRWDV\XP \HWHUVL]OL√∑LGXUXPODU√ïQGD\DUDU O√ïELUHWNLROX√∫WXUDFDN
G¬Å]H\GHROPDG√ï√∑√ïQGDQ √ß√∂zelti EXDPDoODNXOODQ√ïOPDPDO√ïG√ïU
.DOVL\XPNORU¬ÅULULWDQG√ïUEXQHGHQOHX\JXODUNHQGDPDUG√ï√∫√ïQD √ß√∂zelti o√ïNPDPDV√ïQD dikkat 
edilmelidir. 
.DOVL\XP WX]ODU√ï LoHUHQ √ß√∂zeltiler E|EUHN L√∫OHYOHUL ER]XN \D GD VDUNRLGR] JLEL D vitamini 
d√ºzeylerinin \¬ÅNVHNROGX√∑XKDVWDODUGDGLNNDWOLNXOODQ√ïOPDO√ïG√ïU$\U√ïFD b√∂breklerinde NDOVL\XPWD√∫√ï
KLND\HVLEXOXQDQKDVWDODUGDNXOODQ√ïPGDQNDo√ïQ√ïOPDO√ïG√ïU
(√∫]DPDQO√ïRODUDNNDQWUDQVI¬Å]\RQXGD\DS√ïODFDNVDLoHUL√∑LQGHN i kalsiyumun koag√ºlasyona yol 
a√ßabilme riski nedeniyle kanla bi UOLNWHD\Q√ïLQI¬Å]\RQ sisteminden X\JXODQ√ïP√ï|QHULOPH]
/$)/(.6 /$.7$7/, 5√∏1*(5 dg=(/7√∏6√∏ LQI¬Å]\RQX LoHUGL√∑L ODNW DW L\RQODU√ï nedeniyle 
metabolik alkaloz durumuna yol a√ßabilir. 
Kara FL√∑HU \HWPH]OL√∑L olan hastalarda laktat PHWDEROL]PDV√ï ER]XODELOHFH√∑LQGHQ LAFLEKS 
/$.7$7/,5√∏1*(5dg=(/7√∏6√∏DONDOLOH√∫WLULFLHWNLVLQL g√∂steremeyebilir. 
Bu √ß√∂zeltinin NXOODQ√ïP√ïV√ïUDV√ïQGDKDVWDQ√ïQNOLQLNGXUXPXYHODERUDWXYDU parametreleri (kan ve 
idrardaki elektrolit ve glukoz d√ºzeyleri ile asit- ED]GHQJHVLG¬Å]HQOLDUDO√ïNODUOD izlenmelidir. 
Hiperkalemi riski olan hastalarda √∂zellikle plazma potasyum  G¬Å]H\OHUL Do√ïV√ïQGDQ \DN√ïQ
monitorizasyon gerekir. 
√∏ULJDV\RQDPDoO√ïNXOODQ√ïPV√ïUDV√ïQGDGDX\JXODPDODUV√ïUDV√ïQGDVLV WHPLNGROD√∫√ïPDJHoHELOHFH√∑LQGHQ
konjestif NDOS\HWPH]OL√∑LVRQG|QHPE|EUHN\HWPH]OL√∑L sodyum ND\QDNO√ï|GHPOHVH\UHGHQNOLQLN
tablolarda ve kortikosteroid kullanan hastalara uygulamada dikkat gerekir. 
√á√∂zeltiye HNOHQHFHNKHUKDQJLELUED√∫NDLODoODRODELOHFHNELUJHoLPVL]OLN ULVNLQLHQ aza indirmek 
LoLQNDU√ï√∫W√ïUPDL√∫OHPLQGHQKHPHQVRQUDX\JXODPDGDQ|QFHYHX\JXODPDV √ïUDV√ïQGDEHOLUOLDUDODUOD
LQI¬Å]\RQX\DS√ïODFDNVRQNDU√ï√∫√ïPGDKHUKDQJLELUEXODQ√ïNO√ïNYH\Do|NHOPH ROXSROPDG√ï√∑√ïNRQWURO
edilmelidir. 
8\JXODPD NRQWUROO¬Å ELU LQI¬Å]\RQ SRPSDV√ï\OD \DS√ïOD caksa, torba t√ºm√ºyle ER√∫DOPDGDQ |QFH
SRPSDQ√ïQoDO√ï√∫PDV√ïQ√ïQGXUPX√∫ROGX√∑XQDGLNNDWHGLOPHOLGLU aksi halde hava embolisi ROX√∫DELOLU7Torbada NDOP√ï√∫RODELOHFHNKDYDQHGHQL\OHROX√∫DELOHFHNKDYDHPEROLVLQGHQNDo√ïQPDNL oLQHVQHN
WRUEDODU√ïVHULED√∑ODQW√ïO√ïRODUDNNXOODQPD\√ïQ√ï]
$N√ï√∫K√ï]√ïQ√ïDUWW√ïUPDNDPDF√ï\ODX\JXODPDV√ïUDV√ïQGDWRUEDQ√ïQ V√ïN√ï OPDV√ï uygulamadan √∂nce torba 
LoLQGHNLKDYDWDPRODUDNER√∫DOW√ïOPDG√ï√∑√ïGXUXPODUGDKDYDHPEROLVLQH yol a√ßabilir. 
+DYD\ROOXELULQWUDYHQ|]X\JXODPDVHWLQLQKDYD\ROXDo√ïNNHQNXOODQ√ïOPD V√ïhava embolisiyle 
sonu√ßlanabilir. Hava \ROOXLQWUDYHQ|]X\JXODPDVHWOHULKDYD\ROXDo√ïNNHQ torbalardaki √ß√∂zeltilerin 
LQI¬Å]\RQXQGDNXOODQ√ïOPDO√ïG√ïU
Laktat glukoneogenez LoLQELUVXEVWUDWW√ïU7LSGL\DEHWOLKDVWDODUGD LAFLEKS LAKTATLI 
5√∏1*(5 √á√ñ =(/7√∏6√∏NXOODQ√ïO√ïUNHQEXGXUXPGLNNDWHDO√ïQPDO√ïG√ïU
3HGL\DWULNKDVWDODUGDNXOODQ√ïP
x√áocuklarda /$)/(.6 /$.7$7/, 5√∏1*(5 dg=(/7√∏6√∏¬∂QLQ etkinlik ve g√ºvenli 
NXOODQ√ïP√ï uygun ve L\LNRQWUROO¬ÅoDO√ï√∫PDODUODDUD√∫W√ïU√ïOPDP√ï√∫W√ïUDQFDNW√ïEEL literat√ºrde 
elektrolitli √ß√∂zeltilerin pediyatrik SRS¬ÅODV\RQGD NXOODQ√ïP√ïQ√ï J|VWHUHQ bilgiler 
EXOXQPDNWDG√ïU
xLaktat i√ßeren √ß√∂zeltiler \HQLGR√∑DQ ve 6 aydan k√º√ß√ºk bebeklerde √∂zel dikkatle 
X\JXODQPDO√ïG√ïU
*HUL\DWULNKDVWDODUGDNXOODQ√ïP
Geriyatrik hastalarda inf√ºzyon √ß√∂zeltilerinin t LSLLOHX\JXODPDK√ï]√ïYH hacmini belirlerken, bu \D√∫
JUXEXQGDNDOSE|EUHNNDUDFL√∑HUYHGL√∑HUKDVWDO√ïNODULOH ila√ß NXOODQ√ïP√ïQ√ïQGDKDV√ïNROGX√∑XGLNNDWH
DO√ïQPDO√ïG√ïU
√á√∂zelti, steril setl HUDUDF√ïO√ï√∑√ï\ODLQWUDYHQ|] yoldan X\JXODQ√ïU√∏QWUDYHQ|] uygulamada ku OODQ√ïODQ
VHWOHULQVDDWWHELUGH√∑L√∫WLULOPHVL|QHULOLU
<DOQ√ï]FD √ß√∂zelti EHUUDNVDDPEDODM√ïYHNDSDNODU√ïVD√∑ODPVDNXOODQ√ïQ√ï]
4.5 Di √∑er W√ïEEL¬ÅU¬ÅQOHULOH etkile √∫imler ve di √∑er etkile √∫im √∫ekilleri 
√á√∂zeltinin LoHUGL√∑LVRG\XPODLOL√∫NLOLHWNLOH√∫LPOHU
x6RG\XP YH VX UHWDQVL\RQX\OD LOL√∫NLOL |GHP YH KLSHUWDQVL\RQOD ELUOLNW H
kortikoidler/steroidler ve karbenoksolon. 8√á√∂zeltinin LoHUGL√∑LSRWDV\XPODLOL√∫NLOLHWNLOH√∫LPOHU
x3RWDV\XPWXWXFXGL¬ÅUHWLNOHUWHNED√∫√ïQD\DGDNRPELQHRODUDN amilorid, spironolakton,
triamteren). 
xAnjiyotensin G|Q¬Å√∫W¬ÅU¬ÅF¬Å HQ]LP LQKLELW|UOHUL ve muhtemelen anjiotensin II resept√∂r 
antagonistleri. 
x7DNUROLPXV VLNORVSRULQ SOD]PDGDNL SRWDV\XP NRQVDQWUDV\RQXQX DUWW√ïU√ïUODU YH
hiperkalemik etkilerin a UWDFD√∑√ïE|EUHN\HWPH]OL√∑LGXUXPODU√ïQGDS otansiyel olarak fatal 
hiperkalemiye neden olabilirler). 
√á√∂zeltinin LoHUGL√∑LNDOVL\XPODLOL√∫NLOLHWNLOH√∫LPOHU
x(WNLOHULNDOVL\XPYDUO√ï√∑√ïQGDDUWDQYHFLGGL\DGDIDWDONDUGL\DN DULWPLOHUH neden olabilen 
dijitalis grubundan glikozitler. 
xKalsiyumla birlikt H X\JXODQG√ïNODU√ïQGD KLSHUNDOVHPL\H \RO DoDELOHFHN WL\D]LG grubu 
di√ºretikler ya da D vitamini. 
xKalsiyumla ELUOLNWH X\JXODQG√ïNODU√ïQGD HPLOLPOHUL D]DODQ ELIRVIRQDWODU IO RU¬ÅU ED]√ï
florokinolonlar ve tetrasiklinler. 
x.DOVL\XPODELUOLNWHX\JXODQG√ï√∑√ïQGDIDWDO olabilen seftriakson-kalsiyum tuzu presipitasyonu 
riski nedeniyle seftriakson (Bkz. b√∂l√ºm 4.3. Kontrendikasyonlar). 
√á√∂zeltinin LoHUGL√∑LODNWDWODELNDUERQDWDPHWDEROL]HROXULOL√∫NLOLHWNLOH√∫LPO HU
xLaktat PHWDEROL]PDV√ïVRQXFXROX√∫DQELNDUERQDWLGUDU√ïDONDOLKDOHJHWLUGL√∑LQGH QVDOLVLODWODU
EDUELW¬ÅUDWODUYHOLW\XPJLELDVLGLNLODoODU√ïQE|EUHNOHUGHQDW√ïO√ïPODU√ïD UWDU
xSempatomimetik ila√ßlar (√∂rn efedrin, pseudoefedrin) ve stim√ºlan ila√ßlar (deksamfetamin 
s√ºlfat, fenfluramin hidroklor√ºr) gibi alkali LODoODU√ïQ LVHHOLPLQDV\RQODU√ï\DYD√∫ODG√ï√∑√ïQGDQ
\DU√ï|P¬ÅUOHULX]DU
4.6 Gebelik ve laktasyon 
Genel tavsiye 
Gebelik kategorisi: C9√áocuk do √∑XUPDSRWDQVL\HOLEXOXQDQNDG√ïQODU'R√∑ um kontrol√º (Kontrasepsiyon) 
Hayvanlar ¬Å]HULQGH \DS√ïODQ oDO√ï√∫PDODU JHEHOLN YH -YH\D HPEUL\RQDOIHWDO JHOL√∫LP YH -
YH\DGR√∑XPYH -YH\DGR√∑XPVRQUDV√ïJHOL√∫LP¬Å]HULQGHNLHWNLOHUEDN√ïP√ïQGDQ\HWHUVL] GLUEN]
N√ïV√ïP√∏QVDQODUD\|QHOLNSRWDQVL\HOULVNELOLQPHPHNWHGLU
Gebelik d√∂nemi 
LAFLEKS LAK 7$7/, 5√∏1*(5 dg=(/7√∏6√∏ LOH KD\YDQ ¬ÅUHPH oDO√ï√∫PDODU√ï
JHUoHNOH√∫WLULOPHPL√∫WLU /$)/(.6 /$.7$7/, 5√∏1*(5 dg=(/ 7√∏6√∏¬∂QLQ JHEH NDG√ïQODUD
X\JXODQG√ï√∑√ïQGDIHWXVWDKDVDUD\DGD¬ÅUHPH\HWHQH√∑LQGHER]XOPD\D\RO Do√ïSDoPD\DFD√∑√ïGD
bilinmemektedir. /$)/(.6/$.7$7/,5√∏1*(5dg=(/7√∏6√∏JHEHNDG√ïQODUGDDQFDNo RN
JHUHNOL\VHNXOODQ√ïOPDO√ïG√ïU
Laktasyon d√∂nemi 
%XLODF√ïQDQQHV¬ÅW¬ÅQHJHoLSJHoPHGL√∑LELOLQPHPHNWHGLU%LUoRNLODF√ï QDQQHV¬ÅW¬ÅQHJHoWL√∑L
ELOLQGL√∑LQGHQHP]LUPHNWHRODQDQQHOHUGH/$)/(.6/$.7$7/,5√∏1*( Rdg=(/7√∏6√∏ dikkatle 
NXOODQ√ïOPDO√ïG√ïU
.DOVL\XPXQSODVHQWDGDQJHoWL√∑LYHV¬ÅWHGD√∑√ïOG√ï√∑√ï g√∂z√∂n√ºnde WXWXOPDO√ïG√ïU
√á√∂zeltiye KHUKDQJL ELU LODo NDW√ïODFDNVD NXOODQ√ïODQ LODF√ïQ |]HOOL√∑L YH EX LODF√ïQ JHEHOLN YH
ODNWDV\RQGDNLNXOODQ√ïP√ïD\U√ïFDGH√∑HUOHQGLULOPHOLGLU .
hUHPH\HWHQH√∑L)HUWLOLWH 
Bilinen herhangi bir etkisi yoktur. 
$UDoYHPDNLQHNXOODQ√ïP√ï¬Å]HULQGHNLHWNLOHU 
√∏QI¬Å]\RQ\ROX\ODX\JXODQDQ √ß√∂zeltilerin NXOODQ√ïP√ïV√ïUDV√ïQGDDUDoNXOODQ√ïP√ïSUDWLN\|QGHQP¬ÅPN¬ÅQ
GH√∑LOGLU.XOODQ√ïOG√ïNWDQVRQUDDUDoYHPDNLQHN ullanma √ºzerinde bilinen bir etkisi yoktur. 
4.8√∏stenmeyen etkiler 
8\JXODPDWHNQL√∑LQHED√∑O√ïJ|U¬ÅOHELOHQDGYHUVHWNLOHUDUDV√ïQGDIHEU LOUHDNVL\RQODUHQMHNVL\RQ
\HULQGH HQIHNVL\RQ HQMHNVL\RQ \HULQGH ED√∫OD\DUDN \D\√ïODQ YHQ|] WURPER]  \D GD IOHELW
ekstravazasyon ve hipervolemi bulunur.  
/$)/(.6/$.7$7/,5√∏1*(5dg=(/7√∏6√∏NXOODQ√ïP√ïV√ïUDV√ïQGDJ |U¬ÅOHQ istenmeyen etkiler ve 
J|U¬ÅOHQDGYHUVLODoUHDNVL\RQODU√ïQ√ïQV√ïNO√ïNYH√∫LGGHWLELOLQPH PHVLQHUD√∑PHQD\Q√ïELOH√∫LPGHNL
RUDQ√ïQGDGHNVWUR]NDW√ïOP√ï√∫ √ß√∂zelti LOHJ|U¬ÅOHQDGYHUVLODoUHDNVL\RQODU√ïQ√ïQV√ïNO√ïNYH√∫LGGHWL
V√ïQ√ïIODQG√ïUPDV√ï√∫X√∫HNLOGHGLUdRN\D\J√ïQ¬ï\D\J√ïQ¬ïLOD \D\J√ïQROPD\DQ10 ¬ï LOD  VH\UHN ¬ï 000 ila <1/1.000),  √ßok seyrek, izole raporlar dahil  
(<1/10.000); bilinmiyor (eldeki verilerden hareketle tahmin edilemiyor). 
%D√∑√ï√∫√ïNO√ïNVLVWHPLKDVWDO√ïNODU√ï 
dRN\D\J√ïQ Ale UMLNUHDNVL\RQODUYH\DORNDOL]H\DGD\D\J√ïQ¬ÅUWLNHU deride d√∂k√ºnt√º ve eritem 
YHND√∫√ïQW√ïSUXULWLVJLELDQDILOD ktik/anafilaktoid semptomlar; GHULGH√∫L√∫NLQ lik, g√∂z 
√ßevresi, y√ºz ve/veya larinks √∂demi (Quincke √∂demi) 
0HWDEROL]PDYHEHVOHQPHKDVWDO√ïNODU√ï 
<D\J√ïQ(OHNWUROLWER]XNOXNODU√ï
3VLNL\DWULNKDVWDO√ïNODU 
<D\J√ïQ Anksiyete 
√áok seyrek: Panik atak 
Sinir sistemi KDVWDO√ïNODU√ï 
<D\J√ïQROPD\DQ/DNWDWDED√∑O√ïDONDOR]WDUDI√ïQGDQX\DU√ïODQNDV√ïOPDOD U 
.DUGL\DNKDVWDO√ïNODU 
√áok yay J√ïQ Hiperhidrasyon ve kalp yetmez OL√∑LNDOSKDVWDO√ï√∑√ï\DGD pulmoner √∂demi olan 
hastalarda). 
<D\J√ïQ 7D√∫LNDUGLEUDGLNDUGL
6ROXQXPJ|√∑¬ÅVER]XNOXNODU√ïYHPHGLDVWLQDOKDVWDO√ïNODU 
dRN\D\J√ïQ 1D]DONRQMHV\RQ|NV¬ÅU¬ÅNKDS√∫√ï rma, bronkospazm ve/veya nefes DO√ïSYHUPHGH
zorluk 
<D\J√ïQ *|√∑¬ÅVWHV√ïN√ï√∫PDKLVVLJ|√∑¬ÅVD√∑U√ïV√ïWD√∫LNDUGLYHEUDGLNDUGL\OH beraber) 
'HULYHGHULDOW√ïGRNXKDVWDO√ïNODU√ï 
dRN\D\J√ïQ .D√∫√ïQW√ï (/$)/(.6 /$.7$7/, 5√∏1*(5 dg=(/7√∏6√∏ kullanan KDVWDODU√ïQ
\DNOD√∫√ïNNDGDU√ïQGDSUXULWLVELOGLULOPL√∫WLU
6H\UHOWLOHUHN X\JXODQDQ HN LODoODU√ïQ GD DGYHUV HWNLOHUH \ RO DoDELOHFH√∑L NRQXVXQGD X\DQ√ïN
ROXQPDO√ïG√ïU%|\OHELUGXUXPGDX\JXODQDQHNLODF√ïQ¬ÅU¬ÅQELOJLVLQHEDN√ïOPDO√ïG√ïU11 √∏VWHQPH\HQHWNLOHULQJ|U¬ÅOPHGXUXPXQGDLQI¬Å]\RQNHVLOPHOLKDVWDGH√∑H UOHQGLULOPHOLX\JXQ
WHUDS|WLN |QOHPOHU DO√ïQPDO√ï YH JHUHNOL J|U¬ÅOG¬Å√∑¬ÅQGH torbada kalan √ß√∂zelti inceleme i√ßin 
VDNODQPDO√ïG√ïU
√π¬ÅSKHOLDGYHUVUHDNVL\RQODU√ïQUDSRUODQPDV√ï 
5XKVDWODQG√ïUPD VRQUDV√ï √∫¬ÅSKHOL LODo DGYHUV UHDNVL\RQODU√ïQ√ïQ UDSRUODQPD V√ï E¬Å\¬ÅN |QHP
WD√∫√ïPDNWDG√ïU5DSRUODPD\DS√ïOPDV√ïLODF√ïQ\DUDUULVNGHQJHVLQLQV¬ÅUHNOL RODUDNL]OHQPHVLQHRODQDN
VD√∑ODU 6D√∑O√ïN PHVOH√∑L PHQVXSODU√ïQ√ïQ KHUKDQJL ELU √∫¬ÅSKHOL DGYHUV UHDNVL\RQX 7¬ÅUNL\H
Farmakovijilans Merkezi (T√úFAM)‚Äôa bildirmeleri gerekmektedir. 
(www.titck.gov.tr ; e-posta:tufam@titck.gov.tr; Tel: 0 800 314 00 08; Faks: 0 312 218 35 99). 
4.9 Doz a √∫√ïP√ïYHWHGDYLVL 
$√∫√ïU√ïGR]GD\DGDoRNK√ï]O√ïX\JXODQPDV√ï|]HOOLNOHE|EUHNOHUGHQVRG\XP DW√ïO√ïP√ïQ√ïQER]XNROGX√∑X
GXUXPODUGD|GHPULVNLQHQHGHQRODFDN√∫HNLOGHVXYHVRG\XP\¬ÅNOH nmesine yol a√ßabilir. Bu 
durumda renal diyaliz tedavisine gerek duyulabilir.  
3RWDV\XPXQD√∫√ïU√ïPLNWDUODUGDX\JXODQ√ïP√ï|]HOOLNOHE|EUHN\HWPH]O LNOLhastalarda hiperkalemiye 
\RODoDELOLU+LSHUNDOHPLQLQVHPSWRPODU√ïDUDV√ïQGD ekstremitelerde parestezi, kaslar GD]D\√ïIO√ïN
paralizi, kardiyak aritmiler, kalp bloku, kardiyak arest ve mental konf√ºzyon bulunur. Hiperkalemi 
kalsiyum, ins√ºlin (glukozla birlikte), sodyum bikarbonat, iyon GH√∑L√∫WLULFLUHoLQHOHU\DGDGL\DOL]OH
tedavi edilebilir. 
$√∫√ïU√ïNDOVL\XPYHULOPHVL hiperkalsemiye neden olabilir. Hiperkalseminin VHPSWRPODU√ï DUDV√ïQGD
DQRUHNVLEXODQW√ïNXVPDNRQVWLSDV\RQNDU√ïQD√∑U√ïV√ïNDV]D\√ïIO√ï√∑√ï mental UDKDWV√ï]O√ïNODUSROLGLSVL
poli√ºri, nefrokalsi QR]UHQDOWD√∫ROX√∫XPXYHGDKDD√∑√ïU durumlarda kardiyak aritmiler ve koma 
EXOXQXU.DOVL\XPWX]ODU√ïQ√ïQoRNK√ï]O√ïLQI¬Å]\RQXD√∑√ï]GDWHEH√∫LULPVLWD GD|]HOOLNOH\¬Å]GHROPDN
√ºzere v√ºc XWWDDQLN√ï]DUPD\DYHSHULIHULNYD]RGLODWDV\RQDQHGHQRODELOHFH√∑LJ LELKLSHUNDOVHPLQLQ
ELU oRN ED√∫ND VHPSWRPXQD da yol a√ßabilir. Hafif asemptomatik hiperkalsemi kalsiyum v e 
hiperkalsemiye NDWN√ïGDEXOXQDQ'YLWDPLQLJLELLODoODU√ïQX\JXODQ√ïP√ïQDVRQYHUPHNO HG¬Å]HOLU(√∑HU
hiperkalsemi D√∑√ïULVHORRS di√ºretikleri, hemodiyaliz, kalsitonin, bifosfonat ve trisodyum edetat gibi 
WHGDYLOHUHDFLOHQED√∫ODPDN gerekir. 
6RG\XPODNWDW√ïQD√∫√ïU√ïGR]GDYHULOPHVL|]HOOLNOHE|EUHN\HWPH]O L√∑LRODQ hastalarda hipokalemi ve 
PHWDEROLN DONDOR]D \RO DoDELOLU 6HPSWRPODU√ï DUDV√ïQGD miza√ß GH√∑L√∫LNOLNOHUL KDOVL]OLN soluk 
NHVLOPHVLNDVODUGD]D\√ïIO√ïNYHNDOSDW√ïPODU√ïQGDG¬Å]HQVL zlik bulunur. √ñzellikle hipokalsemik 
hastalarda kaslarda hipertonisite, seyirme ve tetani g√∂r√ºlebi lir. %LNDUERQDWD√∫√ïU√ïGR]XQDED√∑O√ï12 metabolik alkalozun tedavisi esas olarak V√ïY√ï YH HOHNWUROLW GHQJHVLQLQ X\JXQ ELU √∫HNLOGH
d√ºzHOWLOPHVLQGHQROX√∫XU.DOVL\XP klor√ºr ve potasyum eksikliklerinin WDPDPODQPDV√ï|]HOOLNOH
√∂nemlidir. 
$√∫√ïU√ïGR] √ß√∂zeltiye HNOHQHQLODoODUDED√∑O√ïLVHD√∫√ïU√ïGR]DED√∑O√ïEHOLUWL ve semptomlar bu eklenen 
LODF√ïQ|]HOOLNOHULQHED√∑O√ïG√ïU
Tedavi V√ïUDV√ïQGD\DQO√ï√∫O√ïNODGR]D√∫√ïO√ïUVDX\JXODPD\DVRQYHULOPHOL YHKDVWD uygulanan ila√ßla 
LOL√∫NLOL EHOLUWL YH VHPSWRPODU Do√ïV√ïQGDQ L]OHQPHOLGLU *HUHNW L√∑LQGH VHPSWRPDWLN YH GHVWHN
WHGDYLOHULX\JXODQPDO√ïG√ïU
5. FARMAKOLOJ √∏K √ñZELL √∏KLER 
5.1 Farmakodinamik √∂zellikler 
Farmakoterap√∂tik grup: √∏QWUDYHQ|] √ß√∂zeltiler / Elektrolit dengesini etkileyen √ß√∂zeltiler 
ATC kodu: B05B / B05BB01 
/$)/(.6/$.7$7/,5√∏1*(5dg=(/7√∏6√∏¬∂QLQ IDUPDNRGLQDPLN|]HOO LNOHULELOH√∫HQOHULQLQ
(sodyum, potasyum, kalsiyum, klor√ºr ve laktat) farmakolojik √∂zellikler LQGHQROX√∫XU
6RG\XPJLELL\RQODUVRG\XPSRPSDV√ï1D -K-$73D]JLELoH√∫LWOLWUDQVSRUWPHNDQL]PDODU√ïQ√ï
NXOODQDUDNK¬ÅFUH]DU√ïQGDQJHoHUOHU6RG\XPQ|URWUDQVPLV\RQNDUGL\DN HOHNWURIL]\RORMLYHUHQDO
metabolizmada √∂nemli rol oynar. 
Sodyum, ekstrasel√ºler V√ïY√ïQ√ïQED√∫O√ïFDNDW\RQXGXU6HUXPGDQRUPDOV odyum d√ºzeyi 135-145 
mEq/l'dir. 9¬ÅFXWV√ïY√ïODU√ïQ√ïQWHPHOG¬Å]HQOH\LFLVLRODQVRG\XPG¬Å]H\OHULELUo RNPHNDQL]PDLOH
ROGXNoDVDELWRODUDNEXG¬Å]H\OHUGHWXWXOXUgUQH√∑LQVHUXPVRG\XPG¬Å]H\OHUL \¬ÅNVHOGL√∑LQGH
antidi√º UHWLN KRUPRQ VDOJ√ïODQPDV√ï D]DODUDN E|EUHNOHUGHQ VRG\XP DW√ïO√ïP√ï RO XUNHQ VRG\XP
G¬Å]H\OHUL D]DOG√ï√∑√ïQGD DQWLGL¬ÅUHWLN KRUPRQ VDOJ√ïODQPDV√ï DUWDU YH VRG\XPXQ VHUXP G¬Å]H\OHUL
NRUXQPD\DoDO√ï√∫√ïO√ïU
6RG\XPHWNLVLQLSULPHURODUDNY¬ÅFXWWDNLVX\XQGD√∑√ïO√ïP√ïV√ïY√ïGHQJHVL YHY¬ÅFXWV√ïY√ïODU√ïQ√ïQR]PRWLN
EDV√ïQF√ïQ√ïQNRQWURO¬ÅLOHJ|VWHULU6RG\XPD\Q√ï]DPDQGDNORU¬ÅUYHELNDUERQDW LOHELUOLNWHY¬ÅFXW
V√ïY√ïODU√ïQ√ïQDVLW -ED]GHQJHVLQLQG¬Å]HQOHQPHVL\OHGHLOL√∫NLOLGLU
Serumdaki normal d√ºzeyleri 100- P(TORODQHNVWUDVHO¬ÅOHUV√ïY√ïQ√ïQED√∫O√ïFDDQ\RQXRODQNORU¬ÅU
VRG\XPPHWDEROL]PDV√ïQ√ï\DN√ïQGDQL]OHUYHY¬ÅFXGXQ asit-baz GHQJHVLQGHRODQGH√∑L√∫LNOLNOHUNORU¬ÅU
NRQVDQWUDV\RQXQGDRODQGH√∑L√∫LNOLNOHULOH\DQV√ïW√ïO√ïU
.ORU¬ÅUNHPLNGRNXGDG¬Å√∫¬ÅNPLNWDUODUGDYHED√∑GRNXVXQXQED]√ïELOH√∫HQOHULQGH|UQH√∑LQ kolajen 
GRNXGD\¬ÅNVHNPLNWDUODUGDEXOXQXU√∏QWUDVHO¬ÅOHUNORU¬ÅU eritrosit ve gastrik mukozada y√ºksek 13 NRQVDQWUDV\RQGDEXOXQXU$Q\RQYHNDW\RQODU√ïQGHQJHVLE|EUHNOHUOHUHJ¬ÅOHHGLOL U.ORU¬ÅUJHUL
emilimi, genellikle sodyumun geri emilimini takip eder. 
Potasyum intras HO¬ÅOHUV√ïY√ïQ√ïQDQDNDW\RQXGXU asit baz dengesinin idamesi, izotonisite, h√ºcrenin 
elektrodinamik √∂zellikleri i√ßin gereklidir. Potasyum bir√ßok enzimat ik reaksiyon i√ßin √∂nemli bir 
reaktivat√∂rd√ºr; sinir LPSXOVODU√ïQ√ïQ iletilmesi, kalp ve iskelet NDVODU√ïQ√ïQ kontraktilitesi, gastrik  
sekresyonlar, renal fonksiyonlar, doku sentezi YH NDUERQKLGUDW PHWDEROL]PDV√ï JLEL ELUoRN
fizyolojik s√ºre√ß i√ßin \D√∫DPVDO|QHPHVDKLSWLU
Serumda normal potasyum d√ºzeyi 3-4.5 mEq/l'dir. Potasyum d√ºzeyleri \¬ÅNVHOGL√∑L nde b√∂brekler 
EXL\RQXK√ï]ODY¬ÅFXWWDQX]DNOD√∫W√ïU√ïU
3RWDV\XPHNVLNOL√∑LQ|URP¬ÅVN¬ÅOHUL√∫OHYLQER]XOPDV√ïEDUVDNGLODWDV\RQXYH LOHXV ile kendini 
g√∂sterir. 
/$)/(.6/$.7$7/,5√∏1*(5dg=(/7√∏6√∏ klor√ºr, ODNWDWYHHNVWUDVHO¬ÅOHUV√ïY√ïGDNLGL√∑HU √∂nemli 
NDW\RQODU√ï i√ßerd L√∑LQGHQSDUHQWHUDO V√ïY√ïWHGDYLVLQGHNXOODQ√ïODELOHFHN uygun √ß√∂zeltilerden biridir. 
2UJDQL]PDGDNLE¬Å\¬ÅNV√ïY√ïND\√ïSODU√ïQGDHNVWUDVHO¬ÅOHUV√ïY√ïODU√ïQELOH√∫ LPLQGHGH√∑L√∫LNOLN\DSPDGDQ
KDVWDGDNLV√ïY√ïYHHOHNWUROLWGHQJHVLEX √ß√∂zeltiyle VD√∑ODQDELOLU
Organizmadaki asit- ED]GHQJHVLQLQDVLWWDUDIDND\G√ï√∑√ïGXUXPODUGDWHGDYLQLQHVDV√ï ekstrasel√ºler 
V√ïY√ïGDNLELNDUER nat d√ºzeylerini y√ºkseltmektir. Sodyum ELNDUERQDW√ïQGR√∑UXGDQGR√∑UX\DYHULOPHVL
WHKOLNHOLRODELOHFH√∑LQGHQEXDPDoODGDKDoRNODNWDWO√ï √ß√∂zeltiler k XOODQ√ïOPDNWDG√ïU/DNWDWL\RQODU√ï
NDUDFL√∑HUGHPHWDEROL]HHGLOHUHN bikarbonat L\RQODU√ïQ√ïQ\HULQLDO√ïUODUEX√∫HNLOGHSOD]PDGDNL
bikarbonat seviyesini y√ºkseltirler. /$)/(.6 /$.7$7/, 5√∏1*(5 dg=(/7√∏6√∏ metabolik 
asidozda, hem asidoz halini RUWDGDQ NDOG√ïU√ïU KHP de b√∂yle vakalarda daima mevcut olan 
HNVWUDVHO¬ÅOHUV√ïY√ïND\E√ïQ√ïNDU√∫√ïODU
5.2 Farmakokinetik √∂zellikler 
/$)/(.6 /$.7$7/, 5√∏1*(5 dg=(/7√∏6√∏¬∂QLQ IDUPDNRNLQHWLN |]HOOL NOHUL ELOH√∫HQOHULQLQ
(sodyum, potasyum, kalsiyum, klor√ºr ve laktat) farmakokinetik √∂zellikle ULQGHQROX√∫XU
Emilim: 
√∏QWUDYHQ|] yoldan uygulanan ila√ßlar i√ßindeki etkin maddeler uygulamadan hemen s onra 
maks LPXPSOD]PDNRQVDQWUDV\RQODU√ïQDXOD√∫√ïU14 'D√∑√ïO√ïP
5DG\RDNWLIRODUDNL√∫DUHWOHQPL√∫VRG\XP (24 1DHQMHNVL\RQXVRQUDV√ï\DU√ïODQPD √∂mr√º, enjekte edilen 
sodyumun %99'u i√ßin 11-13 g√ºn ve kalan % 
LLoLQELU\√ïOG√ïU'D√∑√ïO√ïP dokulara g√∂re GH√∑L√∫LUNDV
NDUDFL√∑HUE|EUHNN√ïN√ïUGDNYHGHULGHK√ï]O√ïHULWURVLWYHQ|URQODUGD\DYD√∫ NHPLNWHLVHoRN\DYD√∫W√ïU
Ekstrasel√ºler V√ïY√ïGDNL potasyum h√ºcre i√ßine, h√ºcre G√ï√∫√ïQGDNLNRQVDQWUDV\RQXQXQ 40 NDW√ïQDXOD√∫DQD
kadar aktif transport ile girer. Glukoz, ins√ºlin ve oksijen SRWDV\XPXQ K¬ÅFUH LoLQH JLUL√∫LQL
NROD\OD√∫W√ïU√ïU6D√∑O√ïNO√ïHUL√∫NLQOHUGHSOD]PDSRWDV\XPNRQVDQWUDV\RQX -P(TODUDO√ï√∑√ïQGDG√ïU
<HQLGR√∑DQODUGDSOD]PDG¬Å]H\LP(TO
\HNDGDUo√ïNDELOLU Bununla beraber potasyumun plazma 
d√ºzeyleri, h√ºcre i√ßi potasyum d√ºzeylerini tam RODUDN\DQV√ïWPDG√ï√∑√ïQGDQSOD]PDG¬Å]H\OHUQRUPDO
ROGX√∑XKDOGHK¬ÅFUHVHO hipokalemi RODELOLU(NVWUDVHO¬ÅOHUV√ïY√ïGDNLS+GH√∑L√∫LNOLNOHULGHSOD] ma 
potasyum konsantrasyonunun GH√∑L√∫PHVLQHQHGHQROXU Plazma pH' √ïQGDNL √ºnitelik GH√∑L√∫LNOLN
ters RUDQW√ïO√ïRODUDNSOD zma potasyum konsantrasyonunda 0.6 P(TOGH√∑L√∫LNOL√∑H neden olur. 
Klor√ºr, QRUPDOGHNHPLNGRNXGDG¬Å√∫¬ÅNPLNWDUODUGDYHED√∑GRNXVXQXQED]√ï bLOH√∫HQOHULQGH|UQH√∑LQ
kolajen dokuda y√ºksek miktarlarda bulunur. Bunun \DQ√ïQGDHULWURVLWYHJDVWULNPXNR]DGDGD
\¬ÅNVHNNRQVDQWUDV\RQGDEXOXQXU(NVWUDVHO¬ÅOHUV√ïY√ïQ√ïQ ED√∫O√ïFDDQ\RQXRODQNORU ¬ÅU¬ÅQY¬ÅFXWWDNL
G¬Å]H\OHUL VRG\XPXQ NRQVDQWUDV\RQ GH√∑L√∫LNOLNOHUL L le \DN√ïQGDQ LOL√∫NLOLGLU  6RG\XP
PHWDEROL]PDV√ïQGDNLDQRUPDOOLNOHUGHJHQHOOLNOHNORU¬ÅUNRQVDQWUDV\RQXQGDGD GH√∑L√∫LNOLNOHUJ|U¬ÅO¬ÅU
.DOVL\XPKHPK¬ÅFUHLoLKHPGHK¬ÅFUHG√ï√∫√ïG¬Å]H\GHKD\DW√ïQGHYDP √ïLoLQ|QHPOL bir katyondur.  
Gereksinime g√∂re ya plazmada kal √ïU\DGDGRNXODUDGD√∑√ïO√ïU Kalsiyum plasenta ve anne s√ºt√ºne de 
ge√ßer. 
/DNWDWVHUXPGDRNVLGDV\RQODELNDUERQDWDG|Q¬Å√∫¬ÅU.DUDFL√∑HUHGD√∑√ïODQ ODNWDWLVHNDUDFL√∑HUGH
JOXNRQHRJHQH]OHPHWDEROL]HRODUDNELNDUERQDWDG|Q¬Å√∫PHNWHGLU
Biyotransformasyon: 
Sodyum, potasyum, kalsiyum ve klor√ºr herhangi bir biyotransformasyona X√∑UDPD]ODU
Gereksinime g√∂re ya v√ºcu WV√ïY√ïYHGRNXODU√ïQDGD√∑√ïO√ïU\D da elimine edilirler. 
/DNWDW LVH \DNOD√∫√ïN  -2 saat i√ßinde hem oksidasyonla hem de √∂zellikle NDUDFL√∑HUGH 
glukoneogene ]OHPHWDEROL]HRODUDNELNDUERQDWROX√∫XU15 Eliminasyon: 
6RG\XPHVDVRODUDNUHQDO\ROODDW√ïO√ïUIDNDWD\Q√ï]DPDQGDE¬Å\¬ÅNoR√∑XQO X√∑XUHQDO yolla geri emilir. 
$]PLNWDUGDVRG\XPLVHIHoHVYHWHULOHDW√ïO√ïU$√∫√ïU√ïWHUOHPHROPD G√ïNoDGHULLOHLWUDK|QHPVL]GLU
6RG\XPPHWDEROL]PDV√ïQ√ï\DN√ïQGDQL]OH\HQNORU¬ÅUL\RQXGDHVDVRODUD NLGUDUODDW√ïO√ïU B√∂breklerden 
klor√ºr geri emilimi, genellikle sodyumun geri emilimini takip HGHU%XQXQ\DQ√ïQGDWHU\ROX\ODGD
ELUPLNWDUDW√ïOPDNWDG√ïU
Potasyumun %80- 
√ïE|EUHNOHULOHDW√ïO√ïU*HULNDODQ√ïG√ï√∫N√ïLOHYHoRND]ELUN √ïVP√ï da terleme ile 
DW√ïO√ïU3RWDV\XPJORPHU¬ÅOOHUGHILOWUHHGLOLUSURNVLPDOW¬ÅEOHUGHQ JHULHPLOLUYH distal t√ºb√ºllerde Na-
.GH√∑L√∫LPLLOHVHNUHWHHGLOLU3RWDV\XPXQW¬ÅE¬ÅOHUVHNUHV\RQXKLGURMH QL\RQGH√∑L√∫LPLDVL t-baz 
dengesi ve adrenal hormonlardan da etkilenir. 
.DOVL\XPHVDVRODUDNIHoHVLOHDW√ïO√ïUD]PLNWDUGDWHUEH]OHULLO HGHDW√ïOPDNWDG√ïU
'R√∑UXVDOO√ïNGR√∑UXVDOROPD\DQGXUXP :
/$)/(.6/$.7$7/,5√∏1*(5dg=(/7√∏6√∏ |QHULOHQGR]DUDO√ï√∑√ïQGD GR√∑UXVDO farmakokinetik 
g√∂sterir. 
5.3 Klinik √∂ncesi g√ºvenlilik verileri 
√á√∂zeltinin ELOH√∫HQOHULLQVDQYHKD\YDQSOD]PDV√ïQ√ïQIL]\RORMLNELOH√∫HQOHULROGX√∑XQGD QYHNOLQLN
X\JXODPD GXUXPXQGD WRNVLN HWNLOHULQ J|U¬ÅOPHVL EHNOHQPHGL√∑LQGHQ NDUVLQRMHQ PXW DMHQ
potansiyeli ile fertilite ¬Å]HULQGHNLHWNLOHULQLGH√∑HUOHQGLUPHNDPDF√ï\OD LAFLEKS LAKTATLI 
5√∏1*(5dg=(/7√∏6√∏LOHoDO√ï√∫PDODU\DS√ïOPDP√ï√∫W√ïU
√á√∂zelti LoLQHNDW√ïODQLODoODU√ïQHPQL\HWLD\U√ïRODUDNGLNNDWHDO√ïQPDO√ïG√ïU
6. FARMAS√ñT √∏K √ñZELL √∏KLER 
<DUG√ïPF√ïPDGGHOHULQOLVWHVL 
Enjeksiyonluk su
6.2. Ge√ßimsizlikler 
√á√∂zeltiye HNOHQHFHN LODF√ïQ JHoLPOLOL√∑L |QFHGHQ GH√∑HUOHQGLULOPHOLGLU *HoLPOLOLN YHULOHULQLQ
EXOXQDPDPDV√ïGXUXPODU√ïQGD √ß√∂zelti KHUKDQJLELULODoLOHNDU√ï√∫W√ïU√ïOPDPDO√ïG√ïU
/$)/(.6/$.7$7/,5√∏1*(5dg=(/7√∏6√∏ i√ßine ge√ßimli bir ila√ß eklendikten hemen sonra 
NXOODQ√ïOPDO√ïG√ïU16 √∏ODo HNOHQPHVL VRQUDV√ï UHQN GH√∑L√∫LNOL√∑L YHYH\D o|NHOPH o|]¬ÅQPH\H Q ELOH√∫LNOHULQ \D GD
NULVWDOOH√∫PHQLQROXSROPDG√ï√∑√ïQ√ïNRQWUROHGHUHNHNOHQHQLODF√ïQJHoL POLROXSROPDG√ï√∑√ïQDNDUDU
vermek, uygu ODPD\√ï\DSDQKHNLPLQVRUXPOXOX√∑XQGDG√ïU √á√∂zeltiye HNOHQHFHNLODF√ïQJHoLPOLROXS
ROPDG√ï√∑√ïQD HNOHQHFHN LODF√ïQ SURVSHNW¬ÅV¬ÅQGHQ ID\GDODQDUDN NDUDU YHULOPH OL√ß√∂zeltiye ila√ß 
eklemeden √∂nce /$)/(.6 /$.7$7/, 5√∏1*(5 dg=(/7√∏6√∏¬∂QLQ S+¬∂V√ïQGD S+   -7) 
√ß√∂z√ºnebilir ve VWDELOROGX√∑XGR√∑UXODQPDO√ïG√ïU
%LUUHKEHURODUDND√∫D√∑√ïGD/$)/(.6/$.7$7/,5√∏1*(5dg=( /7√∏6√∏ ile ge√ßimsiz LODoODU√ïQ 
ED]√ïODU√ïYHULOPHNWHGLU
/$)/(.6/$.7$7/,5√∏1*(5dg=(/7√∏6√∏LOHJHoLPVL]LODoODUGD QED]√ïODU√ï
xAmino kaproik asit 
xAmfoterisin B 
xKortizon asetat 
xDietilstilbestrol 
xEtamivan 
xEtil alkol 
xFosfat ve karbonat i√ßeren √ß√∂zeltiler 
xOksitetrasiklin 
xThiopental sodyum 
xVersenat disodyum 
/$)/(.6/$.7$7/,5√∏1*(5dg=(/7√∏6√∏LOHN√ïVPHQJHoLPVL]LODo ODUGDQED]√ïODU√ï
xTetrasiklin 12 saat s√ºreyle stabildir. 
xAmpisilin sodyumun %2 - ¬∂O¬ÅN NRQVDQWUDV\RQODU√ï 4 saat, %3‚Äôden daha y√ºksek 
NRQVDQWUDV\RQODU√ï\VDVDDWVWDELOGLU
xMinosiklin 12 saat s√ºreyle stabildir. 
xDoksisiklin 6 saat s√ºreyle stabildir 
6.3. Raf √∂mr√º 
36 ay.17 .XOODQ√ïPV√ïUDV√ïQGDUDI|PU¬Å
0LNUREL\RORMLNDo√ïGDQX\JXODPD\DKD]√ïUODPDL√∫OHPLQLQNRQWUROO¬ÅYHY DOLGHHGLOPL√∫DVHSWLN
NR√∫XOODUGD \DS√ïOPDG√ï√∑√ï GXUXPODUGD KD]√ïUODQG√ïNWDQ KHPHQ VRQUD NXOODQ√ïOP DO√ïG√ïU +HPHQ
NXOODQ√ïOPDG√ï√∑√ï GXUXPODUGD VDNODPD NR√∫XOXQXQ YH V¬ÅUHVLQLQ EHOLUOHQPHVL LO Do
eklen PHVLVH\UHOWPHVLQL\DSDQ√ïQVRUXPOXOX√∑XQGDG√ïU
6.4. Saklamaya y√∂nelik √∂zel tedbirler 
√ñze OELUPXKDID]D√∫DUW√ï\RNWXU¬É&
QLQDOW√ïQGDNLRGDV√ïFDNO√ï√∑√ïQGDVDNODQPDO√ïG√ïU 
$PEDODM√ïQQLWHOL√∑ i ve i√ßeri √∑i
100, 150, 250, 500 ve 1000 ml‚Äôlik PP (polipropilen) torbalarda.
hU¬ÅQ¬ÅQVHWOLYHVHWVL]ROPDN¬Å]HUHLNLIRUPXEXOXQPDNWDG√ïU
6.6 Be √∫HULW√ïEEL¬ÅU¬ÅQGHQDUWDNDODQPDGGHOHULQLPKDV√ïYHGL√∑ er √∂zel √∂nlemler 
7HNNXOODQ√ïPO√ïNW√ïU .√ïVPHQNXOODQ√ïOP√ï√∫ √ß√∂zeltiler VDNODQPDPDO√ïG√ïU 
.√ïVPHQNXOODQ√ïOP√ï√∫ torbalar yeniden ha VWD\DX\JXODQDQVLVWHPOHUHED√∑ODQPDPDO√ïG√ïU
.XOODQPD7DOLPDW√ï 
.XOODQ√ïP|QFHVL √ß√∂zelti kontrol edilmelidir. 
Uygulama steril setlerle intraven√∂z yoldan (irigasyon √ß√∂zeltiyi RODUDNNXOODQ√ïODFDNVDLQWUDDUWLN¬ÅOHU
\ROGDQ\DGDGR√∑UXGDQG|NHUHN\DS√ïO√ïU
<DOQ√ï]FDEHUUDNSDUWLN¬ÅOV¬Å]YHDPEDODME¬ÅW¬ÅQO¬Å√∑¬ÅER]XOPDP√ï√∫ √ºr√ºnler NXOODQ√ïOPDO√ïG√ïU 
8\JXODPDVHWL¬ÅU¬ÅQHLOL√∫WLULOGLNWHQVRQUDX\JXODPD\DHQN√ïVDV¬ÅUHGHED√∫ODQP DO√ïG√ïU
Torbadaki UH]LG¬ÅHOKDYD\DED√∑O√ïRODUDNPH\GDQDJHOHELOHFHNELUKDYDHPEROLVL QL√∂nlemek i√ßin, 
ED√∫NDLQI¬Å]\RQV√ïY√ïODU√ï\ODVHULED√∑ODQW√ï\DS√ïOPDPDO√ïG√ïU
√á√∂zelti VWHULOX\JXODPDVHWLDUDF√ïO√ï√∑√ï\ODDVHSWLNWHNQLNNXOODQ√ïO DUDNX\JXODQPDO√ïG√ïU Sisteme hava 
girmemesi i√ßin uy JXODPDVHWLQGHQNXOODQ√ïP|QFHVLV√ïY√ïJHoLULOPHOLGLU
(NLODoODUDVHSWLNNR√∫XOODUGDELUL√∑QH\DUG√ïP√ïLOHLQI¬Å]\RQ|QFH VLYHV√ïUDV√ïQGDNDW√ïODELOLU2OX√∫DQ
VRQ¬ÅU¬ÅQ¬ÅQL]RWRQLVLWHVLSDUHQWHUDOX\JXODPD\DS√ïOPDGDQ|QFHEHOLUOHQPL√∫ROPDO √ïG√ïU
+DVWD\DX\JXODPDGDQ|QFHHNOHQPL√∫LODF√ïQ √ß√∂zeltiyle W¬ÅP¬Å\OHNDU√ï√∫P√ï√∫ oOPDV√ï gereklidir.  Ek ila√ß 
i√ßeren √ß√∂zeltiler, ila√ß eklenmesinden hemen sonra NXOODQ√ïOPDO√ïG√ïUGDKDVRQUDNXOODQ√ïOPDN¬Å]HUH
VDNODQPDPDO√ïG√ïU18 √á√∂zeltiye HNLODoNDW√ïOPDV√ï\DGD\DQO√ï√∫X\JXODPDWHNQL√∑L¬ÅU¬ÅQH pirojen NRQWDPLQDV\RQXQDED√∑O√ï
DWH√∫ reaksiyonuna neden olabilir. Advers reaksiyon g√∂r√ºlmesi durumunda inf√ºzyon a hemen son 
verilmelidir. 
A√ßmak i√ßin: 
1. '√ï√∫DPEDODM√ïQ VD√∑ODPO√ï√∑√ïQ√ïYHV√ï]√ïQW√ïROXSROPDG√ï√∑√ïQ√ïNRQWUROHGLQL ]DPEDODM hasar g√∂rd√ºyse 
NXOODQPD\√ïQ√ï]
2. .RUX\XFXG√ï√∫DPEDODM√ï\√ïUWDUDNDo√ïQ√ï]
3. Koruyucu ambalaj i√ßindeki WRUEDQ√ïQVD√∑ODPROXSROPDG√ï√∑√ïQ√ïV√ïNDUDNNRQWUROHGLQL]
4. Torba i√ßindeki √ß√∂zeltinin EHUUDNO√ï√∑√ïQ√ïYHLoLQGH\DEDQF√ïPDGGHLoHUPHGL√∑LQLNRQWUROHGLQL]
8\JXODPDKD]√ïUO√ïNODU√ï 
1. 7RUED\√ïDV√ïQ√ï]
2. Uygulama ucundaki koruyucu NDSD√∑√ïo√ïNDU√ïQ√ï]
3. 8\JXODPDVHWLQLQVSD\N√ïQ√ïX\JXODPDXFXQDV√ïN√ïFDEDW√ïU√ïQ√ï] √á√∂zeltinin set i√ßinden ge√ßirilerek 
KDVWD\DX\JXODQPDV√ïLoLQVHWLQNXOODQ√ïPWDOLPDW√ïQDX\XOPDO√ïG√ïU
Ek ila√ß ekleme: 
Dikkat: T√ºm parenteral √ß√∂zeltilerde ROGX√∑XJLEL¬ÅU¬ÅQHHN lenecek t√ºm maddeler √ºr√ºnle ge√ßimli 
ROPDO√ïG√ïU √úr√ºne HNOHPH\DS√ïODFDNVDKDVWD\D uygulamadan √∂nce VRQNDU√ï√∫√ïP√ïQGDJHoLPOLOLN
kontrol edilmelidir. 
Uygulama √∂ncesi ila√ß ekleme 
1. √∏ODoX\JXODPDXFXGH]HQIHNWHHGLOLU
2. Eklenecek ila√ß 19-22 gauge NDO√ïQO√ï√∑√ïQGDNLELUL√∑QHVL olan enjekt√∂rle ila√ß uygulama ucundan 
torba i√ßine X\JXODQ√ïU
3. √á√∂zelti YHLoLQHHNOHQHQLODoL\LFHNDU√ï√∫W√ïU√ïO√ïU3RWDV\XPNORU¬ÅUJLEL \R√∑XQLODoODUGDWRUEDQ√ïQ 
X\JXODPDo√ïN√ï√∫√ïQD\XNDU√ï pozisyondayken hafif√ße YXUXODUDNNDU√ï√∫PDV√ïVD√∑ODQ√ïU
Dikkat: √∏oLQHHNLODoX\JXODQP√ï√∫ torbalar VDNODQPDPDO√ïG√ïU
8\JXODPDV√ïUDV√ïQGDLODoHNOHPH 
1. 6HWLQNOHPSLNDSDW√ïO√ïU
2. √∏ODoX\JXODPDXFXGH]HQIHNWHHGLOLU19 3. Eklenecek ila√ß 19-22 gauge NDO√ïQO√ï√∑√ïQGDNLELUL√∑QHVLRODQHQMHNW|UOHLODoX\JXODPDXFXQGDQ
X\JXODQ√ïU
4. √á√∂zelti DVN√ïV√ïQGDQo√ïNDU√ïO√ïUYHWHUVoHYULOLU
5. Bu pozisyondayken WRUEDQ√ïQX\JXODPDo√ïN√ï√∫√ïYHHQMHNVL\RQJLUL√∫LQHKDILIoHYXUXODUDN √ß√∂zelti ve 
HNLODF√ïQNDU√ï√∫PDV√ïVD√∑ODQ√ïU
6. 7RUED\√ïHVNLNRQXPXQDJHWLUHUHNNOHPSDo√ïO√ïUYHX\JXODPD\DGHYDPHGLOLU
58+6$76$+√∏%√∏ 
063KDUPD√∏ODo6DQYH7LF$√π
8OD√∫26%0DK'&DG1R(UJHQH26%
(UJHQH7(.√∏5'$√∂ 
8. RUHSAT NUMARASI(LARI) 
248/87 
9. √∏/.58+6$77$5√∏+√∏58+6$7<(1√∏/(0(7$5√∏+√∏ 
√∏ONUXKVDWWDULKL 04.03.2013
Ruhsat yenileme tarihi: 
.h%¬∂h1<(1√∏/(10(7$5√∏+√∏ 
13 Nisan 2017 13Nisan 2017 